RIBB merger with DRC Medicine
DRC Medicine (Japan)Revenue $0M (FY2025A (fiscal year ended July 31, 2025; audited)) as reported.
Announced 30 June 2025.
DRC Medicine Ltd. is a Japanese healthcare and biotechnology company founded in 2007 and headquartered in Tokyo, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The company is led by President and CEO Dr. Marumi Okazaki, who emphasized that the SPAC transaction will provide resources to capitalize on favorable industry trends, including the growth of airborne allergens, respiratory diseases, and infectious diseases. DRC Medicine is best known for its proprietary Hydro Silver Titanium® technology, which was initially applied in consumer hygiene products such as masks and towels. The company is now advancing this technology to obtain medical device certification for what it describes as among the world's first therapeutic masks for seasonal allergic rhinitis. Beyond medical devices, DRC Medicine is developing a pipeline of In Vitro Diagnostic (IVD) kits for infectious diseases and allergen detection, combining its proprietary cell-free protein synthesis technology with AI-powered applications to achieve universal diagnostics. The company is also in final negotiations to acquire an innovative ATP-enhancing drug for Parkinson's disease from a drug development company, with the drug currently in clinical trials, which would significantly expand its therapeutic portfolio into neurological therapeutics.
On June 30, 2025, DRC Medicine entered into a definitive Business Combination Agreement with Ribbon Acquisition Corp. (NASDAQ: RIBB), a Tokyo-based Cayman Islands blank check company led by Chairman and CEO Angshuman (Bubai) Ghosh and CFO Zhiyang (Anna) Zhou. Ribbon completed its IPO in January 2025, raising $50 million through the sale of 5 million units at $10.00 each, plus a private placement of 220,000 units to its sponsor. The transaction implies an initial pro forma equity value of approximately $422.15 million for the combined company, with a pre-money equity value of $350 million for DRC Medicine on a fully diluted basis. The deal is expected to deliver approximately $50.42 million in cash proceeds to DRC Medicine, assuming no redemptions by Ribbon's shareholders, which will fund business operations including clinical trials and medical device certification. Current DRC Medicine shareholders will retain 100% of their equity and are expected to own approximately 82.91% of the combined company on a pro forma basis. The transaction structure involves an intermediate holding company incorporated in Japan acquiring DRC Medicine's shares, followed by a share exchange and merger with Ribbon, with the combined entity expected to list on the NASDAQ Global Market.
DRC Medicine is pursuing the SPAC route to public markets to access capital for advancing its diverse portfolio across medical devices, diagnostics, and therapeutics. The company's strategy is driven by a focus on unmet medical needs, AI-assisted discovery, and global healthcare infrastructure transformation, aiming to empower the general public in guarding against allergens, respiratory diseases, and infectious diseases. Ribbon's Ghosh highlighted DRC's experienced management team and R&D capabilities as key factors in the decision to pursue the combination, noting the accelerating growth in the healthcare and biotechnology industry. The SPAC structure allows DRC Medicine to bypass the traditional IPO process while securing funding for clinical trials, device certification, and potential acquisitions such as the Parkinson's drug candidate. Ribbon's shareholders approved an extension of the combination deadline to January 16, 2027, providing additional time to complete the regulatory and approval processes required for the healthcare-related transaction. [verified via Google + 425: DRC Medicine, $422M]
Structure & dilution
SEC-primary termsThe headline number ignores the shares that did not pay $10 — the founder promote, PIPE stock and warrants. This is the same deal with all equity claims counted.
Effective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.
- Sponsor promote
- 20%
- Exchange ratio
Consideration Ratio = Aggregate Merger Consideration / Aggregate Fully Diluted Company Shares, where Aggregate Merger Consideration = $350,000,000 divided by the trust Redemption Price. On Domestication each Parent Class A Ordinary Share converts automatically into one share of PubCo Class A Common Stock; each Parent Unit separates into one share plus one-seventh (1/7) of one Right.more ▾less ▴
Why headline and effective values differ is covered in headline vs effective deal value, in plain English.
The target: DRC Medicine Ltd.
from S-4/AThe business actually being bought — described from SEC primary filings, with projections labelled as projections.
DRC Medicine Ltd. (Tokyo, founded 2007, CEO Dr. Marumi Okazaki) sells Hydro Silver Titanium (HST) antibacterial/allergen-adsorbing consumer hygiene products - chiefly masks and towels sold via merchandise sales plus brand-license royalties - and is trying to convert the HST Sheet mask into a certified therapeutic device for seasonal allergic rhinitis after Japan's PMDA DECLINED approval in March 2024; a pipeline of IVD kits (cell-free protein synthesis tech, AI apps) and a mooted acquisition of an ATP-enhancing Parkinson's-drug developer are still pre-commercial. THE FINANCIAL REALITY VS THE STORY: actual revenue is microscopic and shrinking - $0.676M FY2024A to $0.453M FY2025A (FYE Jul-31; ~88% merchandise, rest royalties) and $0.266M in 9M FY2026 (down 30% y/y) - with net losses of $2.16M/$1.68M/$1.61M (FY2024/FY2025/9M FY2026), cash of just $0.284M, ~$5.84M of bank borrowings partly guaranteed by a significant shareholder, a $4.78M shareholders' deficit and an explicit going-concern qualification; yet the merger prices DRC at a $350M pre-money fully-diluted equity value (~772x FY2025 revenue) with pro forma equity ~$422.15M, existing DRC holders keeping ~82.91%, and only ~$50M trust cash (no-redemption case) as the funding story. Post-closing PubCo expects approximately 10 employees.
Founded 2007.
A reported actual.
DRC Medicine Ltd. — every SPAC that has bid for it, and its listed peers
Expensive or cheap?
vs 2 listed peersA price only means something next to what the same kind of business costs on the stock market. This divides what the buyers are paying by what DRC Medicine Ltd. actually sells, and sets the answer against its closest listed comparables — or says plainly when that cannot be done.
SpacBrain’s read on the price
Priced above its listed peers
The deal values DRC Medicine Ltd. at $416.9M, or 920.3× the FY2025A (fiscal year ended July 31, 2025; audited) actual revenue it actually reported. That is 697.2× what the market pays for its closest listed peers (median 1.32×) — an expensive price.
Post-dilution equity + target net debt.
FY2025A (fiscal year ended July 31, 2025; audited) — a reported actual.
920.3× FY2025A (fiscal year ended July 31, 2025; audited) actual revenue. Put another way: $1 of its annual sales is being bought for $920.30.
$1 of their sales costs $1.32 on the open market. Median of 2 listed companies we judged a true comparable, which individually run from 1.15× to 1.49×. Their share prices are from 14 August 2026, not today.
What qualifies this number
- Struck on the post-dilution value of $411.3M, not the announced $350M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- 8113.T, NNNN, 4967.T, AYTU, WOK, GFCX, 6523.T have no revenue to divide by, so they are shown but left out of the peer median.
The 9 listed companies it is measured against, and why
- 8113.Tno revenue multiple
Unicharm - Japan's dominant hygiene-products maker (masks, personal care); the scaled version of DRC's consumer mask/hygiene merchandise business.
- NNNNno revenue multiple
Operational comp: Medical Equipment, Supplies & Distribution (NEC); small-cap ($1.3bn); shares ivd, medical, device, drug, products, for with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- 4967.Tno revenue multiple
Kobayashi Pharmaceutical - Japanese consumer-healthcare/OTC products company selling branded self-care goods through the same drugstore channels DRC targets.
- AYTUno revenue multiple
Operational comp: Biopharmaceuticals; micro-cap ($20m); shares rhinitis, allergic, deficit, seasonal, sold, are with the target's own description; forward EV/Sales 0.4x.
- QDEL1.49× revenue
QuidelOrtho - respiratory and allergy point-of-care IVD maker; the listed benchmark for the infectious-disease/allergen IVD kits DRC says it is developing.
- WOKno revenue multiple
Operational comp: Medical Equipment, Supplies & Distribution (NEC); micro-cap ($8m); shares masks, mask, holders, devices, medical, sales with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- OSUR1.15× revenue
OraSure Technologies - small-cap consumer-adjacent point-of-care diagnostics; comparable scale-stage IVD economics.
- GFCXno revenue multiple
Operational comp: Corporate Financial Services (NEC); shares approval, pre, post, consumer, bank, financial with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- 6523.Tno revenue multiple
PHC Holdings - Tokyo-listed diagnostics and medical-device group; Japanese-listed comp for the medical-device certification path DRC is pursuing.
Which companies count as comparable is our judgement, written out above so you can disagree with it. The median is what these shares happened to trade at on the date given — not a price anyone is offering for this deal.
In plain English
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.